// App-Quantinova.ai

: Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study

Researchers

Presenter

  • Gili Kenet

Principal Investigators

  • Beatrice Nolan

  • Tadashi Matsushita

  • Guy Young

  • Ting Quan

  • Viridiana Cano

  • Christian Sussebach

  • Shauna Andersson

  • Baisong Mei

  • Marion Afonso

  • Kaan Kavakli

Medical Centers

  • Our Lady's Children's Hospital, Dublin, Ireland

  • Sheba Medical CENTER, Ramat Gan, Israel

  • Ege University Children's Hospital, Clinic of Children's Health and Diseases, Division of Pediatric Hematology, Izmir, Turkey

  • TEL AVIV UNIVERSITY, Tel Aviv, Israel

  • Keck School of Medicine, University of Southern California, Los Angeles, CA

  • Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA

  • Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan

Locations

  • Ireland

  • United States

  • Germany

  • Israel

  • Turkey

  • China

  • Japan

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Open Label

  • Multinational

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved